ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

carfilzomib

Also written as “Carfilzomib”, “Cohort C1 & C2: KTX-1001 + Carfilzomib (KYPROLIS®)” and “Drug: Carfilzomib + Dexamethasone”.

Its studies are mostly in Multiple Myeloma · Amyloidosis · Small Cell Lung Carcinoma · Waldenstrom Macroglobulinemia · Hematologic Neoplasms, led by 5 companies.

Drug pageCarfilzomib: every studyMany companies study it; this page follows only the 33 they lead. All 157 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Apr 16, 201933 company-led studies, 4 open or runningNext primary completion: Apr 1, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Amgen230 open or runningphase 4since Apr 16, 2019Sep 6, 2005none ahead
AbbVieits history only32 open or runningphase 3since Nov 28, 2023Sep 27, 2013Jun 2027phase 2 · NCT02899052
Criteriumits history only30 open or runningphase 2since Oct 19, 2011Oct 19, 2011none ahead
Oncotherapeuticsits history only20 open or runningphase 2since Jan 3, 2013Jan 3, 2013none ahead
Sanofiits history only22 open or runningphase 2since Jan 20, 2023Jan 20, 2023Apr 1, 2027phase 2 · NCT06356571

Also a collaborator on its studies: Bristol-Myers Squibb and Onyx Therapeutics.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Amgen only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 8 studies since Sep 6, 2005.

  1. Feb 10, 2011Phase 3 study in Multiple MyelomaNCT01302392 · 315 enrolled · Australia, Austria, Belgium and more
  2. Mar 28, 2012Phase 3 study in Multiple MyelomaNCT01568866 · 929 enrolled · United States, Australia, Austria and more
  3. Aug 30, 2012Phase 2 study in Multiple MyelomaNCT01677858 · 116 enrolled · United States
  4. Feb 12, 2013Phase 3 study in Multiple MyelomaNCT01818752 · 955 enrolled · United States, Argentina, Australia and more
  5. Sep 6, 20132 phase 1 studiesNCT01949545, NCT01949532
  6. Oct 28, 2013Phase 1 study in Multiple MyelomaNCT01980589 · 22 enrolled · United States
  7. Nov 6, 2013Phase 2 study in Small Cell Lung CarcinomaNCT01987232 · 32 enrolled · United States, Canada, Russian Federation
  8. Dec 23, 2014Phase 1 study in Multiple MyelomaNCT02335983 · 107 enrolled · United States
  9. Apr 6, 2015Phase 3 study in Multiple MyelomaNCT02412878 · 478 enrolled · United States, Australia, Belgium and more
  10. Nov 11, 2016Phase 3 study in RecurrenceNCT03029234 · 126 enrolled · China
  11. Apr 2, 2018Phase 2 study in RecurrenceNCT03512353 · 7 enrolled · United States
  12. Jan 14, 2019Phase 3 study in RecurrenceNCT03859427 · 454 enrolled · United States, Austria, Bulgaria and more
  13. Apr 16, 2019Phase 4 study in Multiple MyelomaNCT03934684 · 101 enrolled · India
  14. Nov 22, 2019Phase 2 study in RecurrenceNCT04191616 · 54 enrolled · United States, Denmark, Estonia and more

TargetBeta

“26S proteasome inhibitor”ChEMBL 37, by rule

Other programs on the same 38 targets

ProgramCompanyFurthest phaseStudies
BortezomibruleJohnson & Johnsonphase 485

Studies

All 23 Amgen leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04191616Recurrence · United States, Denmark, Estonia and more2CompletedNov 30, 202254
NCT03934684Multiple Myeloma · India4CompletedMar 23, 2023101
NCT03859427Recurrence · United States, Austria, Bulgaria and more3CompletedMar 31, 2023454
NCT03512353Recurrence · United States2TerminatedJan 16, 20207
NCT03029234Recurrence · China3CompletedNov 5, 2018126
NCT02412878Multiple Myeloma · United States, Australia, Belgium and more3CompletedJun 15, 2017478
NCT02335983Multiple Myeloma · United States1CompletedOct 28, 2019107
NCT01987232Small Cell Lung Carcinoma · United States, Canada, Russian Federation2CompletedAug 201632
NCT01980589Multiple Myeloma · United States1CompletedMar 201622
NCT01949545Hematologic Neoplasms · United States, France, Netherlands and more1CompletedAug 201546
NCT01949532Multiple Myeloma · United States, Australia, Canada1CompletedApr 201526
NCT01818752Multiple Myeloma · United States, Argentina, Australia and more3CompletedJul 15, 2016955
NCT01677858Multiple Myeloma · United States2CompletedJul 22, 2016116
NCT01568866Multiple Myeloma · United States, Australia, Austria and more3CompletedNov 10, 2014929
NCT01302392Multiple Myeloma · Australia, Austria, Belgium and more3CompletedJul 2014315
NCT01080391Multiple Myeloma · United States, Austria, Belgium and more3CompletedJun 16, 2014792
NCT00884312Multiple Myeloma · United States, Canada2CompletedMay 17, 2017101
NCT00721734Multiple Myeloma · United States2CompletedNov 201250
NCT00603447Multiple Myeloma · United States, Canada1CompletedMay 201384
NCT00531284Ovarian Neoplasms · United States2CompletedOct 2014184
NCT00530816Multiple Myeloma · United States, Canada2CompletedJan 2013164
NCT00511238Multiple Myeloma · United States, Canada2CompletedNov 2010312
NCT00150462Waldenstrom Macroglobulinemia · United States1CompletedOct 200948

How it is read

Names in the registry

  • “Carfilzomib”, 34 entries
  • “carfilzomib”, 3 entries
  • “Cohort C1 & C2: KTX-1001 + Carfilzomib (KYPROLIS®)”, 1 entry
  • “Drug: Carfilzomib + Dexamethasone”, 1 entry
  • “Drug: Carfilzomib + Lenalidomide + Dexamethasone”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.